Market's view on Hikma Pharmaceuticals
Published on April 2024
- There is a perception of the company’s stock being undervalued, with a price-to-earnings (PE) ratio highlighted as particularly low.
- The company has presented a decent trading statement, with a note of a significant dividend increase and exceptional costs needing investigation, mainly opioid-related.
- Observations suggest the healthcare company is profitable and positioned as the best value in the sector.
- Concerns are raised about the company’s credibility, with some stock watchers suggesting it might be untrustworthy.
- The impact of external factors like US drug price controls seems to be limited on the company.
- Discussions about the company’s financial management and potential for a currency-related bonus boost.
- The announcement of a new executive in the injectables division has been noted.
- There is a worry around the stock’s reaction to dividend-related moves and potential triggering of stop-losses.